Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Tetanus Toxoid Vaccine in Pancreatic Cancer
NCT03848182Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetanus toxoid in pancreatic ductal adenocarcinoma (PDAC), sponsored by Albert Einstein College of Medicine. Started Jul 2017; status: terminated.
02
Drugs
tetanus toxoid
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03848182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848182.